Shopping Cart
- Remove All
- Your shopping cart is currently empty
MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $257 | In Stock | |
5 mg | $638 | In Stock | |
10 mg | $912 | In Stock | |
25 mg | $1,370 | In Stock | |
50 mg | $1,850 | In Stock |
Description | MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury. |
Molecular Weight | 270.32 |
Formula | C17H18O3 |
Cas No. | 1895957-18-2 |
Smiles | C(=C/CC1=CC=C(OC)C=C1)\C2=CC(OC)=C(O)C=C2 |
Relative Density. | 1.137 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 27.03 mg/mL (100 mM), Sonication is recommended. ![]() DMSO: 50 mg/mL (184.9 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 5% DMSO+40% PEG300+5% Tween 80+50% Saline: 2.5 mg/mL (9.25 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.